MedPath

SOTIO Biotech AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Phase 1
Recruiting
Conditions
Metastatic Solid Tumor
Advanced Solid Tumor
Interventions
First Posted Date
2023-12-08
Last Posted Date
2024-10-07
Lead Sponsor
SOTIO Biotech AG
Target Recruit Count
40
Registration Number
NCT06163391
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇧🇪

Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerp, Belgium

🇧🇪

Institut Jules Bordet, Anderlecht, Brussels, Belgium

and more 4 locations

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Phase 2
Terminated
Conditions
Colorectal Cancer
Interventions
First Posted Date
2022-11-16
Last Posted Date
2024-07-30
Lead Sponsor
SOTIO Biotech AG
Target Recruit Count
16
Registration Number
NCT05619172
Locations
🇧🇪

Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇪🇸

Hospital Clinic de Barcelona, Barcelona, Spain

and more 5 locations

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Phase 2
Terminated
Conditions
Colorectal Cancer
Castration-resistant Prostate Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Cutaneous Squamous Cell Carcinoma
Interventions
First Posted Date
2022-02-25
Last Posted Date
2024-12-16
Lead Sponsor
SOTIO Biotech AG
Target Recruit Count
166
Registration Number
NCT05256381
Locations
🇬🇪

Evex Hospitals - Caraps Medline, Tbilisi, Georgia

🇧🇪

Institut Jules Bordet, Anderlecht, Belgium

🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 51 locations

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Melanoma
Thyroid Cancer
Renal Cell Carcinoma
Non Small Cell Lung Cancer
Small-cell Lung Cancer
Bladder Cancer
Merkel Cell Carcinoma
Skin Squamous Cell Carcinoma
Microsatellite Instability High
Triple Negative Breast Cancer
Interventions
First Posted Date
2020-01-21
Last Posted Date
2025-01-08
Lead Sponsor
SOTIO Biotech AG
Target Recruit Count
115
Registration Number
NCT04234113
Locations
🇫🇷

Institut Gustave Roussy, Paris, France

🇪🇸

University Hospital Sanchinarro, Madrid, Spain

🇫🇷

Hôpitaux Universitaires de Marseille Timone, Marseille, France

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath